share_log

Altimmune | 3: Initial statement of beneficial ownership of securities-Officer Shutterly Andrew

Altimmune | 3: Initial statement of beneficial ownership of securities-Officer Shutterly Andrew

Altimmune | 3：首次持股声明-高管 Shutterly Andrew
美股sec公告 ·  07/01 18:04
Moomoo AI 已提取核心信息
Andrew Shutterly, the Acting Chief Financial Officer of Altimmune, Inc., filed an Initial Statement of Beneficial Ownership of Securities with the SEC on July 1, 2024. The filing, required under Section 16(a) of the Securities Exchange Act of 1934, details Shutterly's direct ownership of 10,113 shares of common stock and various derivative securities, including stock options and restricted stock units (RSUs). The stock options have exercise prices ranging from $4.48 to $12.88 and vesting periods extending up to 2034. The RSUs are set to vest in annual installments through 2027, contingent upon Shutterly's continued service. This filing provides transparency into the holdings of Altimmune's executives and is a routine disclosure for investors monitoring insider transactions.
Andrew Shutterly, the Acting Chief Financial Officer of Altimmune, Inc., filed an Initial Statement of Beneficial Ownership of Securities with the SEC on July 1, 2024. The filing, required under Section 16(a) of the Securities Exchange Act of 1934, details Shutterly's direct ownership of 10,113 shares of common stock and various derivative securities, including stock options and restricted stock units (RSUs). The stock options have exercise prices ranging from $4.48 to $12.88 and vesting periods extending up to 2034. The RSUs are set to vest in annual installments through 2027, contingent upon Shutterly's continued service. This filing provides transparency into the holdings of Altimmune's executives and is a routine disclosure for investors monitoring insider transactions.
2024年7月1日，Altimmune公司临时首席财务官Andrew Shutterly向SEC提交了《证券持有利益初步报表》。根据证券交易法案第16(a)条的规定，此文件详细说明Shutterly直接持有10113股普通股和各种衍生证券，包括期权和受限股票单位(RSUs)。行权价格为4.48至12.88美元的期权的行权期限延长到2034年。 RSUs将在2027年期间分年度解禁，前提是Shutterly继续服务。此次提交提供了关于Altimmune公司高管持股的透明度，并且对于监控内部交易的投资者而言，这是一项例行披露。
2024年7月1日，Altimmune公司临时首席财务官Andrew Shutterly向SEC提交了《证券持有利益初步报表》。根据证券交易法案第16(a)条的规定，此文件详细说明Shutterly直接持有10113股普通股和各种衍生证券，包括期权和受限股票单位(RSUs)。行权价格为4.48至12.88美元的期权的行权期限延长到2034年。 RSUs将在2027年期间分年度解禁，前提是Shutterly继续服务。此次提交提供了关于Altimmune公司高管持股的透明度，并且对于监控内部交易的投资者而言，这是一项例行披露。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息